OpGen (OPGN) Competitors $4.99 +0.02 (+0.40%) As of 04/29/2025 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock OPGN vs. SERA, CORBF, ATPC, AIRS, EUDA, QIPT, BMGL, XGN, BDSX, and PIIIShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Sera Prognostics (SERA), Global Cord Blood (CORBF), Agape ATP (ATPC), AirSculpt Technologies (AIRS), EUDA Health (EUDA), Quipt Home Medical (QIPT), Basel Medical Group (BMGL), Exagen (XGN), Biodesix (BDSX), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry. OpGen vs. Sera Prognostics Global Cord Blood Agape ATP AirSculpt Technologies EUDA Health Quipt Home Medical Basel Medical Group Exagen Biodesix P3 Health Partners OpGen (NASDAQ:OPGN) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Do analysts prefer OPGN or SERA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OpGen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, OPGN or SERA? OpGen has a beta of -1.61, suggesting that its share price is 261% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Does the MarketBeat Community believe in OPGN or SERA? OpGen received 291 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 52.08% of users gave OpGen an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformOpGenOutperform Votes30152.08% Underperform Votes27747.92% Sera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Does the media favor OPGN or SERA? In the previous week, Sera Prognostics had 2 more articles in the media than OpGen. MarketBeat recorded 3 mentions for Sera Prognostics and 1 mentions for OpGen. Sera Prognostics' average media sentiment score of 0.96 beat OpGen's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OpGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in OPGN or SERA? 2.7% of OpGen shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 43.8% of OpGen shares are held by insiders. Comparatively, 15.8% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is OPGN or SERA more profitable? Sera Prognostics has a net margin of 0.00% compared to OpGen's net margin of -1,140.36%. OpGen's return on equity of 0.00% beat Sera Prognostics' return on equity.Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -287.58% Sera Prognostics N/A -51.73%-36.94% Which has stronger valuation & earnings, OPGN or SERA? OpGen has higher revenue and earnings than Sera Prognostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M15.60-$32.67MN/AN/ASera Prognostics$77K1,457.65-$36.24M-$0.99-3.01 SummarySera Prognostics beats OpGen on 9 of the 15 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.70M$2.90B$5.52B$7.84BDividend YieldN/A31.29%5.11%4.23%P/E RatioN/A13.1922.4018.52Price / Sales15.60185.39399.74103.35Price / CashN/A57.5638.1834.62Price / Book-0.434.806.744.24Net Income-$32.67M-$22.21M$3.22B$248.05M7 Day Performance8.48%4.71%4.33%5.03%1 Month Performance25.69%2.02%-0.82%1.69%1 Year Performance-4.95%15.68%16.67%4.20% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$4.99+0.4%N/A-5.0%$41.70M$2.67M0.00100Analyst ForecastGap DownSERASera Prognostics1.1611 of 5 stars$3.39-0.3%N/A-73.3%$127.68M$77,000.00-3.42120Short Interest ↓CORBFGlobal Cord BloodN/A$0.95+46.2%N/AN/A$115.47M$196.12M0.001,200ATPCAgape ATP0.3366 of 5 stars$2.07+10.7%N/A-46.9%$103.51M$1.32M-2.8440Short Interest ↑AIRSAirSculpt Technologies1.5956 of 5 stars$1.70flat$3.75+120.6%-59.9%$99.58M$180.35M-12.14240Negative NewsGap DownEUDAEUDA Health1.1328 of 5 stars$3.97-1.7%N/A+114.0%$97.77M$3.81M0.002Upcoming EarningsShort Interest ↓News CoverageQIPTQuipt Home Medical2.3235 of 5 stars$2.01+1.0%$6.25+210.9%-40.1%$86.61M$244.72M-11.82800Positive NewsBMGLBasel Medical GroupN/A$4.42-0.7%N/AN/A$81.57M$10.05M0.0036XGNExagen3.5575 of 5 stars$4.43-1.3%$7.50+69.3%+395.0%$79.29M$55.64M-4.71220News CoveragePositive NewsBDSXBiodesix3.5293 of 5 stars$0.50-8.9%$2.95+490.0%-56.1%$72.99M$71.32M-1.28220Upcoming EarningsAnalyst ForecastNews CoveragePIIIP3 Health Partners2.439 of 5 stars$8.67-6.2%$16.25+87.4%-62.6%$62.27M$1.50B-10.32500Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies SERA Competitors CORBF Competitors ATPC Competitors AIRS Competitors EUDA Competitors QIPT Competitors BMGL Competitors XGN Competitors BDSX Competitors PIII Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPGN) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPGN Stock Free OPGN Stock Alerts